Neurocrine Biosciences reported second-quarter 2026 revenues up 39% year over year to $959 million and adjusted earnings up 73% to $2.85 per share, beating consensus estimates. The company raised full-year Ingrezza guidance to $2.825-$2.875 billion, while Crenessity first-half sales reached $337 million, up about 400% year over year. Vykat XR contributed $54 million from May 18 through quarter end, with management expecting sequential growth from the fourth quarter onward. NBIX trades at a forward price-to-sales ratio of 3.69, above its sub-industry average of 2.02 and the Medical sector average of 2.23, though below its five-year median of 5.18. The stock carries a Zacks Rank #3 (Hold) with a Growth Score of A, Value Score of B, Momentum Score of D, and VGM Score of A.
Neurocrine Biosciences IncStrong Q2 earnings beat and raised guidance.
Bristol-Myers Squibb Company
Teva Pharma Industries Ltd ADR